Trial Condition(s):

Atrial Fibrillation

Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation.

Bayer Identifier:

12679

ClinicalTrials.gov Identifier:

NCT00568945

EudraCT Number:

2007-003619-30

Study Completed

Trial Purpose

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Inclusion Criteria
- Male and/or female (without childbearing potential) white patients
 - History of persistent or permanent atrial fibrillation
 - 18 to 75 years of age
Exclusion Criteria
- Patients with high-risk cardiovascular diseases
 - Stroke or myocardial infarction
 - Relevant pathological changes in the ECG or echocardiography
 - Medication affecting ventricular response in Afib

Trial Summary

Enrollment Goal
28
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Capadenoson (BAY68-4986)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

CardioSec Clinical Research GmbH

Erfurt, Germany, 99084

Status
Completed
 

Trial Design